- Home
- ATOS vs PHD Comparison
ATOS vs PHD Comparison
Compare ATOS & PHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PHD
- Stock Information
- Founded
- ATOS 2009
- PHD 2004
- Country
- ATOS United States
- PHD United States
- Employees
- ATOS N/A
- PHD N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PHD Investment Managers
- Sector
- ATOS Health Care
- PHD Finance
- Exchange
- ATOS Nasdaq
- PHD Nasdaq
- Market Cap
- ATOS 140.9M
- PHD 121.9M
- IPO Year
- ATOS 2012
- PHD N/A
- Fundamental
- Price
- ATOS $0.96
- PHD $9.67
- Analyst Decision
- ATOS Strong Buy
- PHD
- Analyst Count
- ATOS 3
- PHD 0
- Target Price
- ATOS $7.00
- PHD N/A
- AVG Volume (30 Days)
- ATOS 952.6K
- PHD 67.7K
- Earning Date
- ATOS 11-12-2024
- PHD 01-01-0001
- Dividend Yield
- ATOS N/A
- PHD 11.43%
- EPS Growth
- ATOS N/A
- PHD N/A
- EPS
- ATOS N/A
- PHD 1.27
- Revenue
- ATOS N/A
- PHD N/A
- Revenue This Year
- ATOS N/A
- PHD N/A
- Revenue Next Year
- ATOS N/A
- PHD N/A
- P/E Ratio
- ATOS N/A
- PHD $7.60
- Revenue Growth
- ATOS N/A
- PHD N/A
- 52 Week Low
- ATOS $0.73
- PHD $8.30
- 52 Week High
- ATOS $2.31
- PHD $9.81
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- PHD 36.98
- Support Level
- ATOS $1.17
- PHD $9.59
- Resistance Level
- ATOS $1.30
- PHD $9.93
- Average True Range (ATR)
- ATOS 0.08
- PHD 0.06
- MACD
- ATOS -0.02
- PHD -0.03
- Stochastic Oscillator
- ATOS 1.09
- PHD 23.53
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. Its investment objective is to provide a high level of current income and seek the preservation of capital by investing predominantly in floating-rate loans.